Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses

USRE47929E1 · kind E1 · reissue

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Ryan M. Moslin · Princeton, US
• David S. Weinstein · Plainsboro, US
• Stephen T. Wrobleski · Whitehouse Station, US
• John S. Tokarski · Princeton, US
• Shuqun Lin · Newtown, US
• Steven H. Spergel · Warrington, US
• Yanlei Zhang · Princeton, US

Key dates

• Filing date: Nov 27, 2018
• Grant date: Apr 7, 2020
• Expiry date: Nov 27, 2038

Classification

• Technology area (CPC —): General

Abstract

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.